Given this dilemma, shifting focus to alternative weight loss therapies that do not rely on the leptin-melanocortin system - such as GLP-1 RAs, which have distinctly different mechanisms of action - may offer theoretical feasibility for the treatment of MC4R -deficient obesity
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide carry the evidence: STEP for semaglutide (NEJM 2021), SURMOUNT for tirzepatide (NEJM 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM 2024)
GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
Im just trying to be optimistic. This story has been updated to correct the number of MassHealth enrollees under 21 in the state prescribed GLP-1s solely for weight loss
Please reach out to the authors, your Foley relationship partner, or to our Health Care Practice Group and Health Care & Life Sciences Sector with any questions.
